Videos

Sancy Leachman, M.D., Ph.D., professor and chair of the Department of Dermatology and director of the Melanoma Research Program at the Knight Cancer Institute at Oregon Health and Science University, discusses genetic testing for melanoma.

John E. Harris, M.D., Ph.D., of the UMass Chan Medical School in Worcester, Massachusetts, and director of a vitiligo clinic and research center there, discusses some of the insurance issues regarding Opzelura (ruxolitinib) cream.

Erik Jaklitsch of the University of Pittsburgh School of Medicine presented findings today at the annual meeting of the American Academy of Dermatology that suggest that teledermatology might be useful for shortening the time to treatment for melanoma patients.

Eva R. Parker, MD, associate professor of dermatology at Vanderbilt University Medical Center and president of the Nashville Dermatologic Society, addressed how climate change is already increasing the incidence of some skin-related conditions at the annual meeting of the American Academy of Dermatology in New Orleans.

Emma Guttman-Yassky, M.D., Ph.D. of Icahn School of Medicine at Mount Sinai, New York discussed developments in atopic dermatitis treatment, more specifically with therapies like rocatinlimab and other anti-OX4 agents today at the annual American Academy of Dermatology meeting in New Orleans.

Haley Naik, M.D., associate professor of dermatology at the University of California, San Francisco, School of Medicine, led a discussion about hidradenitis suppurativa today at the annual American Academy of Dermatology meeting in New Orleans.

Monica Li, M.D., clinical instructor in Department of Dermatology and Skin Science at University of British Columbia, led a session on advances in microneedling today at the annual meeting of the American Academy of Dermatology in New Orleans.

Medical experts provide insights on the impact of delayed treatment interventions for patients diagnosed with ALS.

Key humanistic burdens, including stressors on patients and family members, are highlighted.

Laynie Dratch, ScM, CGC, discusses the prognosis associated ALS.

Treatment barriers inhibit optimal care for many patients diagnosed with HIV.

Dr. Peskin identifies the significance of payer support in the treatment landscape of MDR HIV.

Jennifer Roggenbuck, MS, LGC, opens a discussion on patient journeys with ALS.

Non–treatment-naïve patient considerations are explored by key opinion leaders.

Medical experts provide an overview of testing considerations for MDR HIV.

In this second part of a two-part video series, Bronwyn Spira of Force Therapeutics talked to Managed Healthcare Executive about CMS' new CPT codes that were introduced in 2022. These codes help more patients in underserved populations receive better access to care as barriers like cost and transportation are removed through remote care.

Bronwyn Spira of Force Therapeutics talked to Managed Healthcare Executive about CMS' new CPT codes that were introduced in 2022. These codes focus on musculoskeletal and respiratory conditions and the data collected from patients affected. According to Spira, these codes help more patients in underserved populations receive better access to care as barriers like cost and transportation are removed through remote care.

Steven Peskin, M.D., MBA, FACP, discusses considerations for payers when identifying patients at risk for drug-resistant HIV.

Health disparities in HIV treatment management are discussed by Drs Peskin and McCray.

Rich Priore, Sc.D., M.H.A., a clinical associate professor in the Department of Health Policy and Management at Tulane University addresses how hospitals will be affected on the cost and revenue side after the COVID-19 Public Health Emergency expires May 11.

The trade association began lobbying in 2019.

Chris Blackley, co-founder and chief executive officer of Prescryptive Health, discusses the laws that states that are implementing to restrict PBM practices and the impact on patients and employers.

Under the Consolidated Appropriations Act of 2023, some Medicare telehealth flexibilities will extend until December 31, 2024, though significant questions remain for the future of telehealth, especially in the Medicare program.

Rich Priore, Sc.D., M.H.A., a clinical associate professor in the Department of Health Policy and Management at Tulane University, said if Americans invested in health prevention and wellness, fewer would be in hospitals and the cost of care would lower.

Founder and managing partner of Third Culture Capital (3CC), Julien Pham, expressed that funding for telehealth is on the decline and will only continue on this path. Pham explained why this is happening and shared alternative routes of care organizations can take to address disparities and improve access to care.

In this video, Dea Belazi, president and chief executive officer of AscellaHealth, discusses how payers will approach specialty drugs.

Dr McCray shares an encounter with “Patient X”, highlighting the barriers and challenges associated with MDR therapies in HIV treatment.

Dr McCray shares an encounter with “Patient X”, highlighting the barriers and challenges associated with MDR therapies in HIV treatment.

In their final thoughts, Julie Parsons, MD, and John Brandsema, MD, share insights on the evolving and future SMA treatment landscape.

Douglas K. Devries, OD, shares his final insights, highlighting prospective emerging treatments for Demodex blepharitis.